Ayurcann Holdings Corp. says it achieved record sales of $55.4 million for its 2025 fiscal year, marking a 21% increase over the previous year.

The Toronto-based company now has more than 80 vape, concentrate and flower products available nationwide, with distribution in over 75% of licensed retail cannabis outlets across Canada. In Ontario, the country’s largest market, the company has products in over 1,500 stores, representing more than 80% penetration. Nationwide, its brands are listed in more than 35,000 dispensary product slots.

“Despite price compression and competitive pressures, our focus on the business-to-consumer market has enabled Ayurcann to expand market share, diversify product offerings, and strengthen brand loyalty nationwide,” said Chief Executive Officer Igal Sudman.

The company attributes its growth to a mix of new product development, operational efficiency improvements, and strong retailer partnerships. Sudman said the company’s strategy remains rooted in “innovation, reliability, and our ability to anticipate market needs.”

The company reported positive adjusted EBITDA of just over $500,000 for the period ending June 30. That compares to a loss of roughly $350,000 in fiscal year 2024.

Alongside its earnings update, Ayurcann announced it will voluntarily delist from the U.S.-based OTCQB Venture Market effective October 30. Its shares will remain publicly traded on the Canadian Securities Exchange under the ticker “AYUR.”

Founded in 2020, Ayurcann has posted sales growth for four straight years, including triple-digit gains between 2021 and 2024. The company says it will continue to focus on strengthening its foothold in Canada while exploring international expansion opportunities.